Source comparison
Best MK-677 Dosage for Bone Density: Research Protocol Comparison
| Study Population | Daily Dose | Duration | Mean IGF-1 Increase | BMD Change (Femoral Neck) | Bone Formation Markers | Professional Assessment ||—|—|—|—|—|—|| Elderly men (65–80 yrs) with osteopenia | 25mg | 24 months | +72% from baseline | +2.0% at 24 months
This comparison does not assign a generated winner or score.
- | Study Population | Daily Dose | Duration | Mean IGF-1 Increase | BMD Change (Femoral Neck) | Bone Formation Markers | Professional Assessment ||—|—|—|—|—|—|| Elderly men (65–80 yrs) with osteopenia | 25mg | 24 months | +72% from baseline | +2.0% at 24 months | P1NP +68%, Osteocalcin +54% | Optimal dose for age-related bone loss; sustained IGF-1 elevation maintained throughout study with minimal adverse effects || Postmenopausal women (55–70 yrs) | 15mg | 12 months | +48% from baseline | +1.2% at 12 months | P1NP +41%, Osteocalcin +38% | Moderate dose effective for maintenance; lower side effect profile but slower BMD accrual compared to 25mg protocols || Mixed elderly cohort (60–75 yrs) | 10mg | 12 months | +38% from baseline | +0.9% at 12 months | P1NP +29%, Osteocalcin +26% | Minimum effective dose for measurable bone density improvement; insufficient for subjects with severe osteopenia (T-score below -2.5) || Elderly men with low baseline IGF-1 (<100 ng/mL) | 20mg | 18 months | +8
- The evidence supports 20–25mg daily as the best MK-677 dosage for bone density improvement in research models examining age-related skeletal decline. Lower doses (10–15mg) produce measurable but modest effects suitable for maintenance or prevention studies, while higher doses consistently deliver clinically significant BMD increases comparable to pharmaceutical osteoporosis interventions.